A study has found that the ipf drug esbriet lowers the risk of irregular heartbeats by nearly 90%. Additionally, real-world data supports the safety of esbriet, as well as another treatment called ofev. The availability of esbriet has also expanded, with a generic version now available in the us, although its cost-effectiveness has been questioned in some reports.